A Perspective on Quantitative Systems Pharmacology Applications to Clinical Drug Development

被引：10

作者：

Bai, Jane P. F. ^{[1
]}

Earp, Justin C. ^{[1
]}

Strauss, David G. ^{[1
]}

Zhu, Hao ^{[1
]}

机构：

[1] US FDA, Off Clin Pharmacol, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA

来源：

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2020年 / 9卷 / 12期

关键词：

D O I：

10.1002/psp4.12567

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：675 / 677

页数：3

共 9 条

[1] Translational Quantitative Systems Pharmacology in Drug Development: from Current Landscape to Good Practices [J].

Bai, Jane P. F. ;

Earp, Justin C. ;

Pillai, Venkateswaran C. .

AAPS JOURNAL, 2019, 21 (04)

[2] TOWARD PHYSIOLOGICAL UNDERSTANDING OF GLUCOSE-TOLERANCE - MINIMAL-MODEL APPROACH [J].

BERGMAN, RN .

DIABETES, 1989, 38 (12) :1512-1527

[3] Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network [J].

Cucurull-Sanchez, Lourdes ;

Chappell, Michael J. ;

Chelliah, Vijayalakshmi ;

Cheung, S. Y. Amy ;

Derks, Gianne ;

Penney, Mark ;

Phipps, Alex ;

Malik-Sheriff, Rahuman S. ;

Timmis, Jon ;

Tindall, Marcus J. ;

van der Graaf, Piet H. ;

Vicini, Paolo ;

Yates, James W. T. .

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (05) :259-272

[4] A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations [J].

Gadkar, K. ;

Budha, N. ;

Baruch, A. ;

Davis, J. D. ;

Fielder, P. ;

Ramanujan, S. .

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (11)

[5] Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation [J].

Kuemmel, Colleen ;

Yang, Yuching ;

Zhang, Xinyuan ;

Florian, Jeffry ;

Zhu, Hao ;

Tegenge, Million ;

Huang, Shiew-Mei ;

Wang, Yaning ;

Morrison, Tina ;

Zineh, Issam .

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (01) :21-28

[6] Verifying and Validating Quantitative Systems Pharmacology and In Silico Models in Drug Development: Current Needs, Gaps, and Challenges [J].

Musuamba, Flora T. ;

Bursi, Roberta ;

Manolis, Efthymios ;

Karlsson, Kristin ;

Kulesza, Alexander ;

Courcelles, Eulalie ;

Boissel, Jean-Pierre ;

Lesage, Raphaelle ;

Crozatier, Cecile ;

Voisin, Emmanuelle M. ;

Rousseau, Cecile F. ;

Marchal, Thierry ;

Alessandrello, Rossana ;

Geris, Liesbet .

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (04) :195-197

[7] Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis [J].

Schmidt, Brian J. ;

Casey, Fergal P. ;

Paterson, Thomas ;

Chan, Jason R. .

BMC BIOINFORMATICS, 2013, 14

[8] Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia[S] [J].

Sokolov, Victor ;

Helmlinger, Gabriel ;

Nilsson, Catarina ;

Zhudenkov, Kirill ;

Skrtic, Stanko ;

Hamren, Bengt ;

Peskov, Kirill ;

Hurt-Camejo, Eva ;

Jansson-Lofmark, Rasmus .

JOURNAL OF LIPID RESEARCH, 2019, 60 (09) :1610-1621

[9] Quantitative Systems Pharmacology: A Regulatory Perspective on Translation [J].

Zineh, Issam .

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (06) :336-339

← 1 →